KRas G12C inhibitors

A compound of the formula:

• wherein:
• A is —OCH2—, —N(R6)CH2—, —OCH2CH2—, —N(R6)CH2CH2—, —CH2OCH2—, or —CH2N(R6)CH2—;
• B is —CH2— or —C(O)—;
• R is —CN, —C(O) C≡CR8, or a group of the formula
• R2 is H, methyl, or —CH2CN;
• R3 and R5 are each independently H, halogen, cyclopropyl, —C1-3 alkyl-cyclopropyl, —C1-6 alkyl optionally substituted 1-3 times with R10, or —O—C1-6 alkyl optionally substituted 1-3 times with R10;
• R4 is a group of the formula
• R is H, halogen, or —C1-6 alkyl optionally substituted 1-3 times with R10;
• R′ is H, or —C1-6 alkyl;
• R6 is H or —C1-6 alkyl optionally substituted 1-3 times with R10;
• R7 is H, halogen, —NR11R12, —CH2NR11R12, —C2-6 alkyl optionally substituted 1-3 times with R10 or —NR13R14, cyclopropyl, —C1-3 alkyl cyclopropyl, or —O—C1-6 alkyl optionally substituted 1-3 times with R10 or —NR13R14;
• R8 is H, —C1-4 alkyl optionally substituted 1-3 times with R10, or —C3-6 cycloalkyl optionally substituted 1-3 times with R10;
• R9 is H, halogen, —CN, C3-6 cycloalkyl, —C1-3 alkyl-C3-6 cycloalkyl, or —C1-6 alkyl optionally substituted 1-3 times with R10;
• R10 is independently at each occurrence halogen, oxygen, hydroxy, —C1-4 alkyl, or —O—C1-4 alkyl;
• R11 and R12 are each independently H, —C1-4 alkyl, or —C1-4 heteroalkyl, wherein R11 and R12 may combine to form a C5-6 heterocycloalkyl;
• and
• R13 and R14 are each independently H or —C1-4 alkyl,
• or a pharmaceutically acceptable salt thereof.